Drug Trial Radar · NCT04824092
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
899
Actual
Start
May 11, 2021
Primary completion
Sep 1, 2026
Study completion Nov 1, 2027
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Apr 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL
Conditions
- Diffuse Large B-cell Lymphoma
Interventions
TafasitamabDrug
Tafasitamab IV infusion will be administered as per the schedule specified in the respective arm.
LenalidomideDrug
Lenalidomide PO will be administered as per the schedule specified in the respective arm.
RituximabDrug
Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
CyclophosphamideDrug
Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
DoxorubicinDrug
Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
VincristineDrug
Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
PrednisoneDrug
Prednisone PO will be administered as per the schedule specified in the respective arm.
Tafasitamab placeboDrug
0.9% saline solution IV infusion will be administered as per the schedule specified in the respective arm.
Lenalidomide placeboDrug
Placebo matching to lenalidomide PO will be administered as per the schedule specified in the respective arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- PFS-INVTime frame: Time from date of randomization until Progressive Disease or death from any cause. In this trial, the primary endpoint is PFS as assessed by the investigator (up to 43 months)
Locations
307 sites in 29 countries. Site status is shown where the registry gives one.
MorphoSys Research Site
Daphne, Alabama
MorphoSys Research Site
Anaheim, California
MorphoSys Research Site
Clovis, California
MorphoSys Research Site
Fullerton, California
MorphoSys Research Site
Harbor City, California
MorphoSys Research Site
Los Angeles, California
MorphoSys Research Site
San Diego, California
MorphoSys Research Site
Whittier, California
MorphoSys Research Site
Aurora, Colorado
MorphoSys Research Site
Jacksonville, Florida
MorphoSys Research Site
Honolulu, Hawaii
MorphoSys Research Site
Wichita, Kansas
MorphoSys Research Site
Lexington, Kentucky
MorphoSys Research Site
Louisville, Kentucky
MorphoSys Research Site
Baltimore, Maryland
MorphoSys Research Site
Bethesda, Maryland
MorphoSys Research Site
Columbia, Maryland
MorphoSys Research Site
Detroit, Michigan
MorphoSys Research Site
Minneapolis, Minnesota
MorphoSys Research Site
Rochester, Minnesota
MorphoSys Research Site
Kansas City, Missouri
MorphoSys Research Site
Lebanon, New Hampshire
MorphoSys Research Site
Florham Park, New Jersey
MorphoSys Research Site
Buffalo, New York
MorphoSys Research Site
Rochester, New York
MorphoSys Research Site
Canton, Ohio
MorphoSys Research Site
Cincinnati, Ohio
MorphoSys Research Site
Eugene, Oregon
MorphoSys Research Site
Danville, Pennsylvania
MorphoSys Research Site
Chattanooga, Tennessee
MorphoSys Research Site
Germantown, Tennessee
MorphoSys Research Site
Nashville, Tennessee
MorphoSys Research Site
Austin, Texas
MorphoSys Research Site
Bedford, Texas
MorphoSys Research Site
Denison, Texas
MorphoSys Research Site
Fort Worth, Texas
MorphoSys Research Site
Houston, Texas
MorphoSys Research Site
McAllen, Texas
MorphoSys Research Site
Tyler, Texas
MorphoSys Research Site
Ogden, Utah
Showing 40 of 307 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.